Notícias e Atividades da Pliant Therapeutics
Presença
Sede: Estados Unidos
Pliant Therapeutics é uma empresa listada sob o símbolo PLRX (US).
Executivos
Veja o organograma con seus 26 executivos principais
Biografias mais buscadas da Pliant Therapeutics
- Bernard Coulie, Chief Executive Officer and Director
- Suzanne Bruhn, Board Member
- Hoyoung Huh, Chairman of the Board
Recentes movimentos de executivos em Pliant Therapeutics
- Hans Hull, Chief Business Officer, deixou a Companhia (Notícia publicada em 27 de novembro de 2025).
Criar um alerta
para seguir os movimentos de executivos da Pliant Therapeutics.
Farmacêutica
Pliant Therapeutics possui 1.913 concorrentes concorrentes Sanofi (França), Eli Lilly (Estados Unidos) e Moderna (Estados Unidos).
Popular M&A news in Farmacêutica
- Contraline acaba de anunciar uma arrecadação de fundos de 93 milhões de dólares. (publicado em 3 de junho de 2026).
- Hims & Hers adquiriu Eucalyptus (publicado em 2 de junho de 2026).
- Apotex preencheu seu dossiê de IPO. Seu símbolo de ação será TSX. (publicado em 2 de junho de 2026).
Outros contatos sugeridos na indústria do Farmacêutica
Notícias
Últimos comunicados de imprensa de Pliant Therapeutics
- Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting | Pliant Therapeutics, Inc.
- Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results | Pliant Therapeutics, Inc.
- Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference | Pliant Therapeutics, Inc.
- Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors | Pliant Therapeutics, Inc.
- Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting | Pliant Therapeutics, Inc.
- Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting | Pliant Therapeutics, Inc.
- Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results | Pliant Therapeutics, Inc.
- Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors | Pliant Therapeutics, Inc.
- Pliant Therapeutics to Participate in the Piper Sandler Healthcare Conference | Pliant Therapeutics, Inc.
- Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results | Pliant Therapeutics, Inc.
- View more press releases Close
Redes sociais sobre Pliant Therapeutics
- Pliant Therapeutics na Wikipedia, Google News e Yahoo Finance
- Pliant Therapeutics na LinkedIn, X (Twitter) e YouTube
